Compare · BIIB vs ELUT
BIIB vs ELUT
Side-by-side comparison of Biogen Inc. (BIIB) and Elutia Inc. (ELUT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BIIB and ELUT operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- BIIB is the larger of the two at $28.44B, about 649.6x ELUT ($43.8M).
- Over the past year, BIIB is up 43.6% and ELUT is down 46.7% - BIIB leads by 90.3 points.
- BIIB has been more active in the news (9 items in the past 4 weeks vs 3 for ELUT).
- BIIB has more recent analyst coverage (25 ratings vs 0 for ELUT).
- Company
- Biogen Inc.
- Elutia Inc.
- Price
- $192.65-1.36%
- $1.00+1.50%
- Market cap
- $28.44B
- $43.8M
- 1M return
- +0.68%
- -1.95%
- 1Y return
- +43.59%
- -46.68%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- News (4w)
- 9
- 3
- Recent ratings
- 25
- 0
Biogen Inc.
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB111 and BIIB112 to treat ophthalmology related diseases; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and TMS-007 to treat acute neurology; BIIB074 and BIIB095 for neuropathic pain; and SB11 and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Ginkgo Bioworks; Capsigen Inc.; and Mirimus, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Latest BIIB
- Biogen upgraded by Needham with a new price target
- Amendment: SEC Form SCHEDULE 13G/A filed by Biogen Inc.
- Biogen's Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy
- EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus
- Biogen Announces Upcoming Kidney Presentations at European Renal Association and American Transplant Congresses
- UCB and Biogen Announce Publication in The Lancet of Positive Dapirolizumab Pegol (DZP) Phase 3 Study Results in Systemic Lupus Erythematosus
- Stoke Therapeutics to Present at Upcoming Investor Conferences in June
- Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson's Disease
- BIIB SHAREHOLDER INVESTIGATION: SueWallSt Investigates Biogen Inc. for Possible Securities Law Violations
- Evercore ISI resumed coverage on Biogen
Latest ELUT
- Director Rakin Kevin gifted 70,000 shares and disposed of 50,000 shares, decreasing direct ownership by 36% to 126,120 units (SEC Form 4)
- A Reno Biotech Just Rang the Nasdaq Bell — Here's Why the Whole Regenerative-Medicine Tape Is Worth Watching
- Elutia Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
- Elutia Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Elutia Reports First Quarter 2026 Results and Highlights NXT-41x Progress Toward $1.5 Billion U.S. Plastic and Reconstructive Surgery Market
- Elutia to Present at the 16th Annual LD Micro Invitational on May 18th
- TELA Bio Announces Strategic Board Refreshment with Four Highly Experienced Commerical Leaders to Accelerate Growth and Drive Path to Profitability; The Company Also Reports Preliminary First Quarter 2026 Revenues
- Elutia to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026
- SEC Form DEFA14A filed by Elutia Inc.
- SEC Form DEF 14A filed by Elutia Inc.